Silo Pharma Secures New Patent for PTSD Treatment

Silo Pharma has announced that the U.S. Patent and Trademark Office will officially issue a new patent on March 4, 2025, further strengthening protection for its lead asset, SPC-15. The patent builds on Silo’s previously granted U.S. Patent 11,491,120 and expands claims for SPC-15, an innovative intranasal therapy designed to treat post-traumatic stress disorder (PTSD). CEO Eric Weisblum emphasized that securing strong intellectual property rights is key to advancing SPC-15 into clinical trials and driving value for Silo’s broader drug pipeline.

SPC-15 is a serotonin 5-HT4 receptor agonist formulated to treat PTSD and anxiety with a novel intranasal delivery system. Its potential qualification for the FDA’s 505(b)(2) regulatory pathway could accelerate its approval process. Silo Pharma is actively collaborating with Columbia University to advance preclinical studies, holding exclusive global rights to the drug’s development and commercialization. This latest patent milestone reinforces Silo’s commitment to pioneering next-generation treatments for psychiatric disorders.